According to Zhitong Finance APP, BAO PHARMA-B (02659) rose more than 7% today, up 5.02% as of press time to HK$8.475, with a turnover of HK$2.1587 million.
On the news front, BAO PHARMA-B has seen a cluster of positive developments recently. According to the company's voluntary announcement on October 20, the Investigational New Drug (IND) application for its self-developed BJ045 injection (subcutaneous injection) has been approved by the National Medical Products Administration, allowing it to conduct clinical trials in China.
The approval of the clinical study marks the company's formation of a synergistic layout of "degrading enzyme + antibody" in the field of antibody-mediated autoimmune diseases.
In addition, data disclosed by the Stock Exchange shows that on October 23, 26, and 27, Chairman of the Board Liu Yanjun collectively increased his holdings by 263,300 shares of BAO PHARMA-B, with a total amount of approximately HK$2.0243 million. After the increase, his latest shareholding stands at approximately 26.4702 million shares, representing a latest shareholding ratio of 17.15%.
This further demonstrates his confidence in the company's development.
Comments